|
Market Closed -
OTC Markets
15:57:58 03/06/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.1052 USD | -2.09% |
|
-18.25% | -87.61% |
| 08-14 | CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 08-13 | Casi Pharmaceuticals, Inc. Announces Management Changes | CI |
| Market Cap | 2.56M 2.25M 2.13M 1.93M 3.63M 246M 3.65M 25.52M 9.86M 126M 9.62M 9.41M 403M | P/E 2024 |
-1.11x | P/E 2025 | -0.33x |
|---|---|---|---|---|---|
| Enterprise Value | 24.42M 21.47M 20.31M 18.42M 34.59M 2.34B 34.79M 243M 93.9M 1.2B 91.67M 89.69M 3.84B | EV / Sales 2024 |
1.75x | EV / Sales 2025 | 1.9x |
| Free-Float |
53.46% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -2.09% | ||
| 1 week | -18.25% | ||
| Current month | -18.25% | ||
| 1 month | -18.25% | ||
| 3 months | -19.00% | ||
| 6 months | -4.27% | ||
| Current year | -87.61% |
| 1 week | 0.11 |  | 0.16 |
| 1 month | 0.11 | | 0.16 |
| Current year | 0.05 | | 1.2 |
| 1 year | 0.05 | | 2.13 |
| 3 years | 0.05 | | 8.48 |
| 5 years | 0.05 | | 12.4 |
| 10 years | 0.05 | | 88.92 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Cory
CEO | Chief Executive Officer | 62 | 20/07/2025 |
Kun Qian
DFI | Director of Finance/CFO | 44 | 15/05/2025 |
Chun Hua Wang
COO | Chief Operating Officer | 54 | 31/12/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
Yue Wu
BRD | Director/Board Member | 62 | 31/03/2013 |
Zhen Bo Su
BRD | Director/Board Member | 50 | 20/03/2023 |
Thomas Folinsbee
BRD | Director/Board Member | 59 | 20/03/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 18/03/26 | Emerging Technology Partners LLC
| Other | Company | 1,097,341 | 7.0830% | |
| 18/03/26 | Panacea Venture
| Other | Company | 4,529,956 | 29.2393% | |
| 18/03/26 | Other | Chief Financial Officer | 75,000 | 0.4841% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.09% | -18.25% | -91.96% | -95.50% | 2.56M | |
| +0.11% | +1.71% | +63.52% | +117.61% | 1,056B | |
| +0.27% | +0.92% | +51.33% | +73.35% | 655B | |
| +0.73% | +0.68% | +20.70% | +74.90% | 471B | |
| -0.49% | -2.99% | +37.91% | +41.03% | 342B | |
| +0.26% | +4.47% | +22.83% | +29.60% | 277B | |
| +1.86% | +0.43% | +14.77% | +14.63% | 257B | |
| +0.85% | +6.35% | +53.17% | +54.39% | 226B | |
| +0.85% | +1.10% | +35.78% | +101.82% | 189B | |
| +0.29% | -2.30% | -28.07% | -60.73% | 170B | |
| Average | +0.17% | +0.87% | +18.00% | +35.11% | 364.29B | |
| Weighted average by Cap. | +0.16% | +1.04% | +40.51% | +69.93% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 28.54M 25.1M 23.73M 21.53M 40.43M 2.74B 40.66M 284M 110M 1.4B 107M 105M 4.49B | 20.71M 18.22M 17.23M 15.62M 29.34M 1.99B 29.51M 206M 79.65M 1.01B 77.76M 76.08M 3.26B |
| Net income | -39.26M -34.53M -32.65M -29.61M -55.62M -3.77B -55.94M -391M -151M -1.92B -147M -144M -6.18B | -48.06M -42.27M -39.97M -36.25M -68.08M -4.61B -68.48M -479M -185M -2.35B -180M -177M -7.56B |
| Net Debt | 6.05M 5.32M 5.03M 4.56M 8.57M 581M 8.62M 60.24M 23.27M 296M 22.71M 22.22M 952M | 21.85M 19.22M 18.18M 16.49M 30.96M 2.1B 31.14M 218M 84.05M 1.07B 82.05M 80.27M 3.44B |
Employees
214
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/09/26 | US$0.1247 | -3.19% | 1,330 |
| 25/09/26 | US$0.1288 | -19.50% | 551 |
| 23/09/26 | US$0.1600 | +24.22% | 2,772 |
| 22/09/26 | US$0.1288 | -.--% | 274 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CASIF Stock
Select your edition
All financial news and data tailored to specific country editions
